当前位置: X-MOL首页最新SCI期刊查询及投稿分析系统 › INVESTIGATIONAL NEW DRUGS杂志
INVESTIGATIONAL NEW DRUGS
基本信息
期刊名称 INVESTIGATIONAL NEW DRUGS
INVEST NEW DRUG
期刊ISSN 0167-6997
期刊官方网站 http://www.springer.com/medicine/internal/journal/10637
是否OA
出版商 Kluwer Academic Publishers
出版周期 Quarterly
始发年份 1983
年文章数 130
最新影响因子 3.0(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学3区 ONCOLOGY 肿瘤学3区
PHARMACOLOGY & PHARMACY 药学3区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 2.87 1.135 0.748
Medicine
Pharmacology (medical)
61 / 232 73%
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
96 / 300 68%
Medicine
Oncology
114 / 321 64%
补充信息
自引率 2.50%
H-index 73
SCI收录状况 Science Citation Index
Science Citation Index Expanded
官方审稿时间
19 days
Submission to first decision
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0167-6997%5BISSN%5D
投稿指南
期刊投稿网址
收稿范围

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

收录体裁
投稿指南
投稿模板
参考文献格式
编辑信息

Editor-in-Chief:

Eric K. Rowinsky
New York, NY, USA

Founding Editor & Associate Editor: Daniel Von Hoff, Tucson, AZ, USA

Associate Editors: 

Todd Fehniger, St. Louis, MO, USA

David Hong, Houston, TX, USA

Razelle Kurzrock, San Diego, CA, USA

John Miller, Wellington, New Zealand

Eric Raymond, Clichy, France

Gary Schwartz, New York, NY, USA


Editorial Advisory Board:

Julie R. Brahmer, Baltimore, MD, USA

Emiliano Calvo, Madrid, Spain

Richard D. Carvajal,New York, NY, USA

Samuel R. Denmeade, Baltimore, MD, USA

Antoine Italiano, Bordeaux, France

Patricia M. LoRusso, New Haven, CT, USA

Christophe Massard, Villejuif, France

Gary William Middleton, Birmingham, UK

Alain Mita, Los Angeles, CA, USA

Monica Mita, Los Angeles, CA, USA

Sun Young Rha, Seoul, Korea

Manish SharmaChicago, IL, USA

Anil Sood, Houston, TX, USA

Alex Sparreboom, Columbus, OH, USA

Josep Tabernero, Barcelona, Spain

Timothy Yap, London, UK


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug